$HRTX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in HERON THERAPEUTICS, INC. /DE/.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in HERON THERAPEUTICS, INC. /DE/. Get notifications about new insider transactions in HERON THERAPEUTICS, INC. /DE/ for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 16 2021 | HRTX | HERON THERAPEUTICS ... | Christian Waage | Director | Sell | S | 17.51 | 300 | 5,254 | 4,100 | 4.4 K to 4.1 K (-6.82 %) |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | Szekeres David Leslie | EVP, Chief Operatin ... | Option Exercise | M | 0.00 | 1,250 | 0 | 17,500 | |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | Szekeres David Leslie | EVP, Chief Operatin ... | Payment of Exercise | F | 16.66 | 433 | 7,214 | 817 | 1.3 K to 817 (-34.64 %) |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | Szekeres David Leslie | EVP, Chief Operatin ... | Buy | M | 0.00 | 1,250 | 0 | 1,250 | 0 to 1.3 K |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Option Exercise | M | 0.00 | 3,646 | 0 | 51,041 | |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Payment of Exercise | F | 16.66 | 963 | 16,044 | 95,192 | 96.2 K to 95.2 K (-1.00 %) |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Buy | M | 0.00 | 3,646 | 0 | 96,155 | 92.5 K to 96.2 K (+3.94 %) |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Gift | G | 0.00 | 600 | 0 | 92,509 | 91.9 K to 92.5 K (+0.65 %) |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Gift | G | 0.00 | 600 | 0 | 0 | 600 to 0 (-100.00 %) |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Buy | J | 0.00 | 600 | 0 | 600 | 0 to 600 |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | President & CCO | Option Exercise | M | 0.00 | 1,250 | 0 | 17,500 | |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | President & CCO | Payment of Exercise | F | 16.66 | 433 | 7,214 | 20,414 | 20.8 K to 20.4 K (-2.08 %) |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | President & CCO | Buy | M | 0.00 | 1,250 | 0 | 20,847 | 19.6 K to 20.8 K (+6.38 %) |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | Peraza Lisa | VP, Chief Accountin ... | Option Exercise | M | 0.00 | 552 | 0 | 7,729 | |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | Peraza Lisa | VP, Chief Accountin ... | Payment of Exercise | F | 16.66 | 191 | 3,182 | 11,945 | 12.1 K to 11.9 K (-1.57 %) |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | Peraza Lisa | VP, Chief Accountin ... | Buy | M | 0.00 | 552 | 0 | 12,136 | 11.6 K to 12.1 K (+4.77 %) |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | EVP, Drug Developme ... | Option Exercise | M | 0.00 | 1,250 | 0 | 17,500 | |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | EVP, Drug Developme ... | Payment of Exercise | F | 16.66 | 433 | 7,214 | 1,634 | 2.1 K to 1.6 K (-20.95 %) |
Apr 15 2021 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | EVP, Drug Developme ... | Buy | M | 0.00 | 1,250 | 0 | 2,067 | 817 to 2.1 K (+153.00 %) |
Apr 07 2021 | HRTX | HERON THERAPEUTICS ... | Johnson Craig A | Director | Sell | S | 17.22 | 250 | 4,305 | 3,590 | 3.8 K to 3.6 K (-6.51 %) |
Jan 15 2021 | HRTX | HERON THERAPEUTICS ... | Szekeres David Leslie | EVP, Chief Operatin ... | Option Exercise | M | 0.00 | 1,250 | 0 | 18,750 | |
Jan 15 2021 | HRTX | HERON THERAPEUTICS ... | Szekeres David Leslie | EVP, Chief Operatin ... | Sell | S | 18.09 | 827 | 14,960 | 0 | 827 to 0 (-100.00 %) |
Jan 15 2021 | HRTX | HERON THERAPEUTICS ... | Szekeres David Leslie | EVP, Chief Operatin ... | Payment of Exercise | F | 18.16 | 423 | 7,682 | 827 | 1.3 K to 827 (-33.84 %) |
Jan 15 2021 | HRTX | HERON THERAPEUTICS ... | Szekeres David Leslie | EVP, Chief Operatin ... | Buy | M | 0.00 | 1,250 | 0 | 1,250 | 0 to 1.3 K |
Jan 15 2021 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | President & CCO | Option Exercise | M | 0.00 | 1,250 | 0 | 18,750 | |
Jan 15 2021 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | President & CCO | Payment of Exercise | F | 18.16 | 433 | 7,863 | 19,597 | 20 K to 19.6 K (-2.16 %) |
Jan 15 2021 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | President & CCO | Buy | M | 0.00 | 1,250 | 0 | 20,030 | 18.8 K to 20 K (+6.66 %) |
Jan 15 2021 | HRTX | HERON THERAPEUTICS ... | Peraza Lisa | VP, Chief Accountin ... | Option Exercise | M | 0.00 | 552 | 0 | 8,281 | |
Jan 15 2021 | HRTX | HERON THERAPEUTICS ... | Peraza Lisa | VP, Chief Accountin ... | Payment of Exercise | F | 18.16 | 227 | 4,122 | 11,584 | 11.8 K to 11.6 K (-1.92 %) |
Jan 15 2021 | HRTX | HERON THERAPEUTICS ... | Peraza Lisa | VP, Chief Accountin ... | Buy | M | 0.00 | 552 | 0 | 11,811 | 11.3 K to 11.8 K (+4.90 %) |
Jan 15 2021 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | EVP, Drug Developme ... | Option Exercise | M | 0.00 | 1,250 | 0 | 18,750 | |
Jan 15 2021 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | EVP, Drug Developme ... | Payment of Exercise | F | 18.16 | 433 | 7,863 | 817 | 1.3 K to 817 (-34.64 %) |
Jan 15 2021 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | EVP, Drug Developme ... | Buy | M | 0.00 | 1,250 | 0 | 1,250 | 0 to 1.3 K |
Jan 08 2021 | HRTX | HERON THERAPEUTICS ... | Szekeres David Leslie | EVP, Chief Operatin ... | Sell | S | 19.66 | 3,571 | 70,219 | 0 | 3.6 K to 0 (-100.00 %) |
Dec 23 2020 | HRTX | HERON THERAPEUTICS ... | Christian Waage | Director | Option Exercise | A | 19.46 | 18,000 | 350,280 | 18,000 | |
Dec 23 2020 | HRTX | HERON THERAPEUTICS ... | Christian Waage | Director | Grant | A | 0.00 | 3,000 | 0 | 4,400 | 1.4 K to 4.4 K (+214.29 %) |
Dec 23 2020 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | President & CCO | Buy | J | 11.65 | 637 | 7,423 | 18,780 | 18.1 K to 18.8 K (+3.51 %) |
Dec 23 2020 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | EVP, Drug Developme ... | Option Exercise | M | 13.00 | 10,000 | 130,000 | 48,416 | |
Dec 23 2020 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | EVP, Drug Developme ... | Sell | S | 20.00 | 10,000 | 200,000 | 0 | 10 K to 0 (-100.00 %) |
Dec 23 2020 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | EVP, Drug Developme ... | Buy | M | 13.00 | 10,000 | 130,000 | 10,000 | 0 to 10 K |
Dec 23 2020 | HRTX | HERON THERAPEUTICS ... | Johnson Craig A | Director | Option Exercise | A | 19.46 | 18,000 | 350,280 | 18,000 | |
Dec 23 2020 | HRTX | HERON THERAPEUTICS ... | Johnson Craig A | Director | Grant | A | 0.00 | 3,000 | 0 | 3,840 | 840 to 3.8 K (+357.14 %) |
Dec 23 2020 | HRTX | HERON THERAPEUTICS ... | DAVIS STEPHEN | Director | Option Exercise | A | 19.46 | 18,000 | 350,280 | 18,000 | |
Dec 23 2020 | HRTX | HERON THERAPEUTICS ... | DAVIS STEPHEN | Director | Grant | A | 0.00 | 3,000 | 0 | 3,000 | 0 to 3 K |
Oct 15 2020 | HRTX | HERON THERAPEUTICS ... | Peraza Lisa | VP, Chief Accountin ... | Option Exercise | A | 0.00 | 8,833 | 0 | 8,833 | |
Oct 15 2020 | HRTX | HERON THERAPEUTICS ... | Peraza Lisa | VP, Chief Accountin ... | Option Exercise | A | 15.72 | 103,000 | 1,619,160 | 103,000 | |
Oct 15 2020 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | EVP, Drug Developme ... | Option Exercise | A | 0.00 | 20,000 | 0 | 20,000 | |
Oct 15 2020 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | EVP, Drug Developme ... | Option Exercise | A | 15.72 | 120,000 | 1,886,400 | 120,000 | |
Oct 15 2020 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | President & CCO | Option Exercise | A | 0.00 | 20,000 | 0 | 20,000 | |
Oct 15 2020 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | President & CCO | Option Exercise | A | 15.72 | 170,000 | 2,672,400 | 170,000 | |
Oct 15 2020 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Option Exercise | A | 0.00 | 58,333 | 0 | 58,333 | |
Oct 15 2020 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Option Exercise | A | 15.72 | 350,000 | 5,502,000 | 350,000 | |
Oct 15 2020 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Buy | J | 12.12 | 1,158 | 14,036 | 89,226 | 88.1 K to 89.2 K (+1.31 %) |
Oct 15 2020 | HRTX | HERON THERAPEUTICS ... | Christian Waage | Director | Option Exercise | A | 15.72 | 437 | 6,870 | 437 | |
Oct 15 2020 | HRTX | HERON THERAPEUTICS ... | DAVIS STEPHEN | Director | Option Exercise | A | 15.72 | 765 | 12,026 | 765 | |
May 01 2020 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Sell | S | 13.97 | 1,158 | 16,176 | 0 | 1.2 K to 0 (-100.00 %) |
May 01 2020 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Buy | J | 12.12 | 1,158 | 14,036 | 1,158 | 0 to 1.2 K |
Apr 17 2020 | HRTX | HERON THERAPEUTICS ... | Christian Waage | Director | Option Exercise | A | 14.44 | 713 | 10,296 | 713 | |
Apr 17 2020 | HRTX | HERON THERAPEUTICS ... | DAVIS STEPHEN | Director | Option Exercise | A | 14.44 | 1,426 | 20,591 | 1,426 | |
Dec 23 2019 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Option Exercise | A | 25.02 | 325,000 | 8,131,500 | 325,000 | |
Dec 23 2019 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | EVP, Chief Commerci ... | Option Exercise | A | 25.02 | 55,562 | 1,390,161 | 55,562 | |
Dec 23 2019 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Option Exercise | A | 25.02 | 120,000 | 3,002,400 | 120,000 | |
Dec 23 2019 | HRTX | HERON THERAPEUTICS ... | HOFFMAN ROBERT | CFO & SVP, Finance | Option Exercise | A | 25.02 | 100,000 | 2,502,000 | 100,000 | |
Dec 23 2019 | HRTX | HERON THERAPEUTICS ... | Christian Waage | Director | Option Exercise | A | 25.02 | 17,000 | 425,340 | 17,000 | |
Dec 23 2019 | HRTX | HERON THERAPEUTICS ... | Johnson Craig A | Director | Option Exercise | A | 25.02 | 23,000 | 575,460 | 23,000 | |
Dec 23 2019 | HRTX | HERON THERAPEUTICS ... | DAVIS STEPHEN | Director | Option Exercise | A | 25.02 | 15,500 | 387,810 | 15,500 | |
Dec 23 2019 | HRTX | HERON THERAPEUTICS ... | TANG KEVIN C | Director | Option Exercise | A | 25.02 | 17,000 | 425,340 | 17,000 | |
Dec 03 2019 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Option Exercise | M | 13.00 | 24,000 | 312,000 | 58,416 | |
Dec 03 2019 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Sell | S | 26.00 | 24,000 | 624,000 | 0 | 24 K to 0 (-100.00 %) |
Dec 03 2019 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Buy | M | 13.00 | 24,000 | 312,000 | 24,000 | 0 to 24 K |
Oct 07 2019 | HRTX | HERON THERAPEUTICS ... | TANG KEVIN C | Director | Buy | P | 17.50 | 285,714 | 4,999,995 | 5,799,810 | 5.5 M to 5.8 M (+5.18 %) |
Oct 04 2019 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Buy | P | 17.50 | 4,571 | 79,993 | 94,652 | 90.1 K to 94.7 K (+5.07 %) |
Oct 04 2019 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Buy | P | 17.50 | 4,571 | 79,993 | 94,652 | 90.1 K to 94.7 K (+5.07 %) |
Oct 04 2019 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Buy | J | 18.43 | 806 | 14,853 | 90,081 | 89.3 K to 90.1 K (+0.90 %) |
Oct 04 2019 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Buy | J | 18.43 | 806 | 14,853 | 90,081 | 89.3 K to 90.1 K (+0.90 %) |
Oct 04 2019 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | EVP, Chief Commerci ... | Buy | P | 17.50 | 5,143 | 90,003 | 18,143 | 13 K to 18.1 K (+39.56 %) |
Oct 04 2019 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | EVP, Chief Commerci ... | Buy | P | 17.50 | 5,143 | 90,003 | 18,143 | 13 K to 18.1 K (+39.56 %) |
Oct 01 2019 | HRTX | HERON THERAPEUTICS ... | DAVIS STEPHEN | Director | Option Exercise | A | 17.56 | 750 | 13,170 | 750 | |
Oct 01 2019 | HRTX | HERON THERAPEUTICS ... | DAVIS STEPHEN | Director | Option Exercise | A | 17.56 | 25,000 | 439,000 | 25,000 | |
Jul 17 2019 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | EVP, Chief Commerci ... | Option Exercise | A | 18.29 | 300,000 | 5,487,000 | 300,000 | |
May 23 2019 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | Director | Buy | P | 17.55 | 3,000 | 52,650 | 13,000 | 10 K to 13 K (+30.00 %) |
May 16 2019 | HRTX | HERON THERAPEUTICS ... | Christian Waage | Director | Buy | P | 18.04 | 1,400 | 25,262 | 1,400 | 0 to 1.4 K |
May 02 2019 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Sell | S | 18.86 | 1,109 | 20,918 | 0 | 1.1 K to 0 (-100.00 %) |
May 02 2019 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Buy | J | 18.43 | 1,109 | 20,437 | 1,109 | 0 to 1.1 K |
Dec 18 2018 | HRTX | HERON THERAPEUTICS ... | Rosen Robert | President | Option Exercise | A | 24.97 | 300,000 | 7,491,000 | 300,000 | |
Dec 18 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Option Exercise | A | 24.97 | 300,000 | 7,491,000 | 300,000 | |
Dec 18 2018 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Option Exercise | A | 24.97 | 100,000 | 2,497,000 | 100,000 | |
Dec 18 2018 | HRTX | HERON THERAPEUTICS ... | HOFFMAN ROBERT | CFO & SVP, Finance | Option Exercise | A | 24.97 | 71,000 | 1,772,870 | 71,000 | |
Dec 18 2018 | HRTX | HERON THERAPEUTICS ... | Christian Waage | Director | Option Exercise | A | 24.97 | 17,000 | 424,490 | 17,000 | |
Dec 18 2018 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | Director | Option Exercise | A | 24.97 | 30,000 | 749,100 | 30,000 | |
Dec 18 2018 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | Director | Option Exercise | A | 24.97 | 19,500 | 486,915 | 19,500 | |
Dec 18 2018 | HRTX | HERON THERAPEUTICS ... | Johnson Craig A | Director | Option Exercise | A | 24.97 | 21,000 | 524,370 | 21,000 | |
Dec 18 2018 | HRTX | HERON THERAPEUTICS ... | TANG KEVIN C | Director | Option Exercise | A | 24.97 | 17,000 | 424,490 | 17,000 | |
Nov 02 2018 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Sell | S | 30.62 | 494 | 15,125 | 0 | 494 to 0 (-100.00 %) |
Nov 02 2018 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Buy | J | 23.60 | 494 | 11,656 | 494 | 0 to 494 |
Oct 02 2018 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Option Exercise | M | 13.00 | 6,000 | 78,000 | 82,416 | |
Oct 02 2018 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Sell | S | 32.07 | 6,000 | 192,433 | 0 | 6 K to 0 (-100.00 %) |
Oct 02 2018 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Buy | M | 13.00 | 6,000 | 78,000 | 6,000 | 0 to 6 K |
Sep 14 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Option Exercise | M | 7.20 | 19,675 | 141,660 | 710,601 | |
Sep 14 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Buy | M | 7.20 | 19,675 | 141,660 | 89,275 | 69.6 K to 89.3 K (+28.27 %) |
Sep 12 2018 | HRTX | HERON THERAPEUTICS ... | TANG KEVIN C | Director | Sell | S | 35.75 | 2,695,000 | 96,346,250 | 5,830,215 | 8.5 M to 5.8 M (-31.61 %) |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Option Exercise | M | 13.00 | 6,000 | 78,000 | 88,416 | |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Sell | S | 38.85 | 100 | 3,885 | 0 | 100 to 0 (-100.00 %) |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Sell | S | 37.51 | 5,900 | 221,294 | 100 | 6 K to 100 (-98.33 %) |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Buy | M | 13.00 | 6,000 | 78,000 | 6,000 | 0 to 6 K |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | HOFFMAN ROBERT | CFO & SVP, Finance | Option Exercise | M | 15.30 | 30,000 | 459,000 | 100,000 | |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | HOFFMAN ROBERT | CFO & SVP, Finance | Sell | S | 38.80 | 1,060 | 41,123 | 1,280 | 2.3 K to 1.3 K (-45.30 %) |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | HOFFMAN ROBERT | CFO & SVP, Finance | Sell | S | 38.15 | 28,940 | 1,104,107 | 2,340 | 31.3 K to 2.3 K (-92.52 %) |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | HOFFMAN ROBERT | CFO & SVP, Finance | Buy | M | 15.30 | 30,000 | 459,000 | 31,280 | 1.3 K to 31.3 K (+2,343.75 %) |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | HOFFMAN ROBERT | CFO & SVP, Finance | Buy | J | 13.22 | 744 | 9,834 | 1,280 | 536 to 1.3 K (+138.81 %) |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | Rosen Robert | President | Option Exercise | M | 7.20 | 95,531 | 687,823 | 600,000 | |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | Rosen Robert | President | Option Exercise | M | 7.20 | 129,469 | 932,177 | 695,531 | |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | Rosen Robert | President | Sell | S | 38.75 | 3,400 | 131,765 | 2,640 | 6 K to 2.6 K (-56.29 %) |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | Rosen Robert | President | Sell | S | 38.13 | 92,131 | 3,512,918 | 6,040 | 98.2 K to 6 K (-93.85 %) |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | Rosen Robert | President | Buy | M | 7.20 | 95,531 | 687,823 | 98,171 | 2.6 K to 98.2 K (+3,618.60 %) |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | Rosen Robert | President | Sell | S | 41.39 | 2,112 | 87,415 | 2,640 | 4.8 K to 2.6 K (-44.44 %) |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | Rosen Robert | President | Sell | S | 40.17 | 51,696 | 2,076,597 | 4,752 | 56.4 K to 4.8 K (-91.58 %) |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | Rosen Robert | President | Sell | S | 39.14 | 75,661 | 2,961,122 | 56,448 | 132.1 K to 56.4 K (-57.27 %) |
Jul 03 2018 | HRTX | HERON THERAPEUTICS ... | Rosen Robert | President | Buy | M | 7.20 | 129,469 | 932,177 | 132,109 | 2.6 K to 132.1 K (+4,904.13 %) |
Jun 22 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Option Exercise | M | 9.05 | 50,000 | 452,500 | 250,000 | |
Jun 22 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Sell | S | 39.05 | 50,000 | 1,952,500 | 69,600 | 119.6 K to 69.6 K (-41.81 %) |
Jun 22 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Buy | M | 9.05 | 50,000 | 452,500 | 119,600 | 69.6 K to 119.6 K (+71.84 %) |
Jun 22 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Buy | J | 13.22 | 1,607 | 21,241 | 69,600 | 68 K to 69.6 K (+2.36 %) |
Jun 22 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Option Exercise | M | 9.05 | 50,000 | 452,500 | 250,000 | |
Jun 22 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Sell | S | 39.05 | 50,000 | 1,952,500 | 69,600 | 119.6 K to 69.6 K (-41.81 %) |
Jun 22 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Buy | M | 9.05 | 50,000 | 452,500 | 119,600 | 69.6 K to 119.6 K (+71.84 %) |
Jun 22 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Buy | J | 13.22 | 1,607 | 21,241 | 69,600 | 68 K to 69.6 K (+2.36 %) |
Apr 02 2018 | HRTX | HERON THERAPEUTICS ... | TANG KEVIN C | Director | Buy | P | 26.00 | 192,308 | 5,000,008 | 8,525,215 | 8.3 M to 8.5 M (+2.31 %) |
Mar 19 2018 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Option Exercise | M | 13.00 | 18,000 | 234,000 | 94,416 | |
Mar 19 2018 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Sell | S | 30.00 | 18,000 | 540,000 | 0 | 18 K to 0 (-100.00 %) |
Mar 19 2018 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Buy | M | 13.00 | 18,000 | 234,000 | 18,000 | 0 to 18 K |
Mar 19 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Option Exercise | M | 7.20 | 100,000 | 720,000 | 730,276 | |
Mar 19 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Sell | S | 29.75 | 100,000 | 2,975,000 | 67,993 | 168 K to 68 K (-59.53 %) |
Mar 19 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Buy | M | 7.20 | 100,000 | 720,000 | 167,993 | 68 K to 168 K (+147.07 %) |
Mar 16 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Option Exercise | M | 7.20 | 100,000 | 720,000 | 830,276 | |
Mar 16 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Sell | S | 24.75 | 100,000 | 2,475,000 | 67,993 | 168 K to 68 K (-59.53 %) |
Mar 16 2018 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Buy | M | 7.20 | 100,000 | 720,000 | 167,993 | 68 K to 168 K (+147.07 %) |
Jan 12 2018 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Option Exercise | M | 13.00 | 7,584 | 98,592 | 112,416 | |
Jan 12 2018 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Sell | S | 20.00 | 7,584 | 151,680 | 0 | 7.6 K to 0 (-100.00 %) |
Jan 12 2018 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Buy | M | 13.00 | 7,584 | 98,592 | 7,584 | 0 to 7.6 K |
Dec 20 2017 | HRTX | HERON THERAPEUTICS ... | Christian Waage | Director | Option Exercise | A | 17.00 | 17,000 | 289,000 | 17,000 | |
Dec 20 2017 | HRTX | HERON THERAPEUTICS ... | POYHONEN JOHN | Director | Option Exercise | A | 17.00 | 19,500 | 331,500 | 19,500 | |
Dec 20 2017 | HRTX | HERON THERAPEUTICS ... | Johnson Craig A | Director | Option Exercise | A | 17.00 | 21,000 | 357,000 | 21,000 | |
Dec 20 2017 | HRTX | HERON THERAPEUTICS ... | TANG KEVIN C | Director | Option Exercise | A | 17.00 | 17,000 | 289,000 | 17,000 | |
Dec 20 2017 | HRTX | HERON THERAPEUTICS ... | Rosen Robert | President | Option Exercise | A | 17.00 | 310,000 | 5,270,000 | 310,000 | |
Dec 20 2017 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Option Exercise | A | 17.00 | 310,000 | 5,270,000 | 310,000 | |
Dec 20 2017 | HRTX | HERON THERAPEUTICS ... | Quart Barry D | Chief Executive Off ... | Buy | J | 12.62 | 1,684 | 21,256 | 67,993 | 66.3 K to 68 K (+2.54 %) |
Dec 20 2017 | HRTX | HERON THERAPEUTICS ... | MANHARD KIMBERLY | Executive VP, Drug ... | Option Exercise | A | 17.00 | 120,000 | 2,040,000 | 120,000 | |
Dec 20 2017 | HRTX | HERON THERAPEUTICS ... | HOFFMAN ROBERT | CFO & SVP, Finance | Option Exercise | A | 17.00 | 56,667 | 963,339 | 56,667 | |
Dec 20 2017 | HRTX | HERON THERAPEUTICS ... | HOFFMAN ROBERT | CFO & SVP, Finance | Buy | J | 13.05 | 536 | 6,993 | 536 | 0 to 536 |